Skip to main content
Top
Published in: Abdominal Radiology 10/2023

12-07-2023 | Hepatocellular Carcinoma | Hepatobiliary

Nomogram based on Sonazoid contrast-enhanced ultrasound to differentiate intrahepatic cholangiocarcinoma and poorly differentiated hepatocellular carcinoma: a prospective multicenter study

Authors: Shuo Wang, Jundong Yao, Kaiyan Li, Hong Yang, Shichun Lu, Guangzhi He, Wei Wu, Wen Cheng, Tianan Jiang, Hong Ding, Xiang Jing, Yuanyuan Yan, Fangyi Liu, Jie Yu, Zhiyu Han, Zhigang Cheng, Shuilian Tan, Xin Li, Jianping Dou, Yunlin Li, Erpeng Qi, Yiqiong Zhang, Ping Liang, Xiaoling Yu

Published in: Abdominal Radiology | Issue 10/2023

Login to get access

Abstract

Objectives

The aim of this study was to develop a predictive model based on Sonazoid contrast-enhanced ultrasound (SCEUS) and clinical features to discriminate poorly differentiated hepatocellular carcinoma (P-HCC) from intrahepatic cholangiocarcinoma (ICC).

Patients and method

Forty-one ICC and forty-nine P-HCC patients were enrolled in this study. The CEUS LI-RADS category was assigned according to CEUS LI-RADS version 2017. Based on SCEUS and clinical features, a predicated model was established. Multivariate logistic regression analysis and LASSO logistic regression were used to identify the most valuable features, 400 times repeated 3-fold cross-validation was performed on the nomogram model and the model performance was determined by its discrimination, calibration, and clinical usefulness.

Results

Multivariate logistic regression and LASSO logistic regression indicated that age (> 51 y), viral hepatitis (No), AFP level (≤  20 µg/L), washout time (≤  45 s), and enhancement level in the Kupffer phase (Defect) were valuable predictors related to ICC. The area under the receiver operating characteristic (AUC) of the nomogram was 0.930 (95% CI: 0.856–0.973), much higher than the subjective assessment by the sonographers and CEUS LI-RADS categories. The calibration curve showed that the predicted incidence was more consistent with the actual incidence of ICC, and 400 times repeated 3-fold cross-validation revealed good discrimination with a mean AUC of 0.851. Decision curve analysis showed that the nomogram could increase the net benefit for patients.

Conclusions

The nomogram based on SCEUS and clinical features can effectively differentiate P-HCC from ICC

Graphical abstract

Appendix
Available only for authorised users
Literature
1.
go back to reference Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71:209-249.CrossRefPubMed Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71:209-249.CrossRefPubMed
2.
go back to reference Sahu SK, Chawla YK, Dhiman RK, Singh V, Duseja A, Taneja S, Kalra N, et al. Rupture of Hepatocellular Carcinoma: A Review of Literature. J Clin Exp Hepatol 2019;9:245-256.CrossRefPubMed Sahu SK, Chawla YK, Dhiman RK, Singh V, Duseja A, Taneja S, Kalra N, et al. Rupture of Hepatocellular Carcinoma: A Review of Literature. J Clin Exp Hepatol 2019;9:245-256.CrossRefPubMed
3.
go back to reference European Association for the Study of the Liver Ea, easloffice easloffice eu, European Association for the Study of the L. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018;69:182-236. European Association for the Study of the Liver Ea, easloffice easloffice eu, European Association for the Study of the L. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018;69:182-236.
4.
6.
go back to reference Patrone R, Izzo F, Palaia R, Granata V, Nasti G, Ottaiano A, Pasta G, et al. Minimally invasive surgical treatment of intrahepatic cholangiocarcinoma: A systematic review. World J Gastrointest Oncol 2021;13:2203-2215.CrossRefPubMedPubMedCentral Patrone R, Izzo F, Palaia R, Granata V, Nasti G, Ottaiano A, Pasta G, et al. Minimally invasive surgical treatment of intrahepatic cholangiocarcinoma: A systematic review. World J Gastrointest Oncol 2021;13:2203-2215.CrossRefPubMedPubMedCentral
7.
go back to reference Galassi M, Iavarone M, Rossi S, Bota S, Vavassori S, Rosa L, Leoni S, et al. Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound. Liver Int 2013;33:771-779.CrossRefPubMed Galassi M, Iavarone M, Rossi S, Bota S, Vavassori S, Rosa L, Leoni S, et al. Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound. Liver Int 2013;33:771-779.CrossRefPubMed
9.
go back to reference Boozari B, Soudah B, Rifai K, Schneidewind S, Vogel A, Hecker H, Hahn A, et al. Grading of hypervascular hepatocellular carcinoma using late phase of contrast enhanced sonography - a prospective study. Dig Liver Dis 2011;43:484-490.CrossRefPubMed Boozari B, Soudah B, Rifai K, Schneidewind S, Vogel A, Hecker H, Hahn A, et al. Grading of hypervascular hepatocellular carcinoma using late phase of contrast enhanced sonography - a prospective study. Dig Liver Dis 2011;43:484-490.CrossRefPubMed
10.
go back to reference Jang HJ, Kim TK, Burns PN, Wilson SR. Enhancement patterns of hepatocellular carcinoma at contrast-enhanced US: comparison with histologic differentiation. Radiology 2007;244:898-906.CrossRefPubMed Jang HJ, Kim TK, Burns PN, Wilson SR. Enhancement patterns of hepatocellular carcinoma at contrast-enhanced US: comparison with histologic differentiation. Radiology 2007;244:898-906.CrossRefPubMed
11.
go back to reference Hatanaka K, Kudo M, Minami Y, Maekawa K. Sonazoid-enhanced ultrasonography for diagnosis of hepatic malignancies: comparison with contrast-enhanced CT. Oncology 2008;75 Suppl 1:42-47.CrossRefPubMed Hatanaka K, Kudo M, Minami Y, Maekawa K. Sonazoid-enhanced ultrasonography for diagnosis of hepatic malignancies: comparison with contrast-enhanced CT. Oncology 2008;75 Suppl 1:42-47.CrossRefPubMed
12.
go back to reference Sugimoto K, Moriyasu F, Saito K, Taira J, Saguchi T, Yoshimura N, Oshiro H, et al. Comparison of Kupffer-phase Sonazoid-enhanced sonography and hepatobiliary-phase gadoxetic acid-enhanced magnetic resonance imaging of hepatocellular carcinoma and correlation with histologic grading. J Ultrasound Med 2012;31:529-538.CrossRefPubMed Sugimoto K, Moriyasu F, Saito K, Taira J, Saguchi T, Yoshimura N, Oshiro H, et al. Comparison of Kupffer-phase Sonazoid-enhanced sonography and hepatobiliary-phase gadoxetic acid-enhanced magnetic resonance imaging of hepatocellular carcinoma and correlation with histologic grading. J Ultrasound Med 2012;31:529-538.CrossRefPubMed
13.
go back to reference Li C, Xu J, Liu Y, Wu M, Dai W, Song J, Wang H. Kupffer Phase Radiomics Signature in Sonazoid-Enhanced Ultrasound is an Independent and Effective Predictor of the Pathologic Grade of Hepatocellular Carcinoma. J Oncol 2022;2022:6123242.PubMedPubMedCentral Li C, Xu J, Liu Y, Wu M, Dai W, Song J, Wang H. Kupffer Phase Radiomics Signature in Sonazoid-Enhanced Ultrasound is an Independent and Effective Predictor of the Pathologic Grade of Hepatocellular Carcinoma. J Oncol 2022;2022:6123242.PubMedPubMedCentral
14.
go back to reference Dietrich CF, Nolsoe CP, Barr RG, Berzigotti A, Burns PN, Cantisani V, Chammas MC, et al. Guidelines and Good Clinical Practice Recommendations for Contrast-Enhanced Ultrasound (CEUS) in the Liver-Update 2020 WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. Ultrasound Med Biol 2020;46:2579-2604.CrossRefPubMed Dietrich CF, Nolsoe CP, Barr RG, Berzigotti A, Burns PN, Cantisani V, Chammas MC, et al. Guidelines and Good Clinical Practice Recommendations for Contrast-Enhanced Ultrasound (CEUS) in the Liver-Update 2020 WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. Ultrasound Med Biol 2020;46:2579-2604.CrossRefPubMed
15.
go back to reference Washington MK, Goldberg RM, Chang GJ, Limburg P, Lam AK, Salto-Tellez M, Arends MJ, et al. Diagnosis of digestive system tumours. Int J Cancer 2021;148:1040-1050.CrossRefPubMed Washington MK, Goldberg RM, Chang GJ, Limburg P, Lam AK, Salto-Tellez M, Arends MJ, et al. Diagnosis of digestive system tumours. Int J Cancer 2021;148:1040-1050.CrossRefPubMed
16.
go back to reference Lee JY, Minami Y, Choi BI, Lee WJ, Chou YH, Jeong WK, Park MS, et al. The AFSUMB Consensus Statements and Recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound using Sonazoid. Ultrasonography 2020;39:191-220.CrossRefPubMedPubMedCentral Lee JY, Minami Y, Choi BI, Lee WJ, Chou YH, Jeong WK, Park MS, et al. The AFSUMB Consensus Statements and Recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound using Sonazoid. Ultrasonography 2020;39:191-220.CrossRefPubMedPubMedCentral
17.
go back to reference Radiology ACo. CEUS LI-RADS version 2017. In: American College of Radiology; 2017. Radiology ACo. CEUS LI-RADS version 2017. In: American College of Radiology; 2017.
18.
go back to reference Cannella R, Furlan A. Mosaic architecture of hepatocellular carcinoma. Abdom Radiol (NY) 2018;43:1847-1848.CrossRefPubMed Cannella R, Furlan A. Mosaic architecture of hepatocellular carcinoma. Abdom Radiol (NY) 2018;43:1847-1848.CrossRefPubMed
19.
go back to reference Dietrich CF, Dong Y, Kono Y, Caraiani C, Sirlin CB, Cui XW, Tang A. LI-RADS ancillary features on contrast-enhanced ultrasonography. Ultrasonography 2020;39:221-228.CrossRefPubMedPubMedCentral Dietrich CF, Dong Y, Kono Y, Caraiani C, Sirlin CB, Cui XW, Tang A. LI-RADS ancillary features on contrast-enhanced ultrasonography. Ultrasonography 2020;39:221-228.CrossRefPubMedPubMedCentral
20.
go back to reference Kang HJ, Kim JH, Yoo J, Han JK. Diagnostic criteria of perfluorobutane-enhanced ultrasonography for diagnosing hepatocellular carcinoma in high-risk individuals: how is late washout determined? Ultrasonography 2022;41:530-542.CrossRefPubMed Kang HJ, Kim JH, Yoo J, Han JK. Diagnostic criteria of perfluorobutane-enhanced ultrasonography for diagnosing hepatocellular carcinoma in high-risk individuals: how is late washout determined? Ultrasonography 2022;41:530-542.CrossRefPubMed
21.
go back to reference Li L, Zheng W, Wang J, Han J, Guo Z, Hu Y, Li X, et al. Contrast-Enhanced Ultrasound Using Perfluorobutane: Impact of Proposed Modified LI-RADS Criteria on Hepatocellular Carcinoma Detection. AJR Am J Roentgenol 2022;219:434-443.CrossRefPubMed Li L, Zheng W, Wang J, Han J, Guo Z, Hu Y, Li X, et al. Contrast-Enhanced Ultrasound Using Perfluorobutane: Impact of Proposed Modified LI-RADS Criteria on Hepatocellular Carcinoma Detection. AJR Am J Roentgenol 2022;219:434-443.CrossRefPubMed
22.
go back to reference Huang Z, Zhou P, Li S, Li K. Evaluation of contrast-enhanced ultrasound LI-RADS version 2017: application on 271 liver nodules in individuals with non-alcoholic steatohepatitis. Eur Radiol 2022. Huang Z, Zhou P, Li S, Li K. Evaluation of contrast-enhanced ultrasound LI-RADS version 2017: application on 271 liver nodules in individuals with non-alcoholic steatohepatitis. Eur Radiol 2022.
23.
go back to reference Matsumoto N, Ogawa M, Takayasu K, Hirayama M, Miura T, Shiozawa K, Abe M, et al. Quantitative sonographic image analysis for hepatic nodules: a pilot study. J Med Ultrason (2001) 2015;42:505-512. Matsumoto N, Ogawa M, Takayasu K, Hirayama M, Miura T, Shiozawa K, Abe M, et al. Quantitative sonographic image analysis for hepatic nodules: a pilot study. J Med Ultrason (2001) 2015;42:505-512.
24.
go back to reference Yanagisawa K, Moriyasu F, Miyahara T, Yuki M, Iijima H. Phagocytosis of ultrasound contrast agent microbubbles by Kupffer cells. Ultrasound Med Biol 2007;33:318-325.CrossRefPubMed Yanagisawa K, Moriyasu F, Miyahara T, Yuki M, Iijima H. Phagocytosis of ultrasound contrast agent microbubbles by Kupffer cells. Ultrasound Med Biol 2007;33:318-325.CrossRefPubMed
25.
go back to reference Shunichi S, Hiroko I, Fuminori M, Waki H. Definition of contrast enhancement phases of the liver using a perfluoro-based microbubble agent, perflubutane microbubbles. Ultrasound Med Biol 2009;35:1819-1827.CrossRefPubMed Shunichi S, Hiroko I, Fuminori M, Waki H. Definition of contrast enhancement phases of the liver using a perfluoro-based microbubble agent, perflubutane microbubbles. Ultrasound Med Biol 2009;35:1819-1827.CrossRefPubMed
26.
go back to reference Barr RG, Huang P, Luo Y, Xie X, Zheng R, Yan K, Jing X, et al. Contrast-enhanced ultrasound imaging of the liver: a review of the clinical evidence for SonoVue and Sonazoid. Abdom Radiol (NY) 2020;45:3779-3788.CrossRefPubMed Barr RG, Huang P, Luo Y, Xie X, Zheng R, Yan K, Jing X, et al. Contrast-enhanced ultrasound imaging of the liver: a review of the clinical evidence for SonoVue and Sonazoid. Abdom Radiol (NY) 2020;45:3779-3788.CrossRefPubMed
27.
go back to reference Korenaga K, Korenaga M, Furukawa M, Yamasaki T, Sakaida I. Usefulness of Sonazoid contrast-enhanced ultrasonography for hepatocellular carcinoma: comparison with pathological diagnosis and superparamagnetic iron oxide magnetic resonance images. J Gastroenterol 2009;44:733-741.CrossRefPubMed Korenaga K, Korenaga M, Furukawa M, Yamasaki T, Sakaida I. Usefulness of Sonazoid contrast-enhanced ultrasonography for hepatocellular carcinoma: comparison with pathological diagnosis and superparamagnetic iron oxide magnetic resonance images. J Gastroenterol 2009;44:733-741.CrossRefPubMed
28.
go back to reference Zou RH, Lin QG, Huang W, Li XL, Cao Y, Zhang J, Zhou JH, et al. Quantitative Contrast-Enhanced Ultrasonic Imaging Reflects Microvascularization in Hepatocellular Carcinoma and Prognosis after Resection. Ultrasound Med Biol 2015;41:2621-2630.CrossRefPubMed Zou RH, Lin QG, Huang W, Li XL, Cao Y, Zhang J, Zhou JH, et al. Quantitative Contrast-Enhanced Ultrasonic Imaging Reflects Microvascularization in Hepatocellular Carcinoma and Prognosis after Resection. Ultrasound Med Biol 2015;41:2621-2630.CrossRefPubMed
29.
go back to reference Lv K, Zhai H, Jiang Y, Liang P, Xu HX, Du L, Chou YH, et al. Prospective assessment of diagnostic efficacy and safety of Sonazoid(TM) and SonoVue((R)) ultrasound contrast agents in patients with focal liver lesions. Abdom Radiol (NY) 2021;46:4647-4659.CrossRefPubMed Lv K, Zhai H, Jiang Y, Liang P, Xu HX, Du L, Chou YH, et al. Prospective assessment of diagnostic efficacy and safety of Sonazoid(TM) and SonoVue((R)) ultrasound contrast agents in patients with focal liver lesions. Abdom Radiol (NY) 2021;46:4647-4659.CrossRefPubMed
30.
go back to reference Sugimoto K, Kakegawa T, Takahashi H, Tomita Y, Abe M, Yoshimasu Y, Takeuchi H, et al. Usefulness of Modified CEUS LI-RADS for the Diagnosis of Hepatocellular Carcinoma Using Sonazoid. Diagnostics (Basel) 2020;10. Sugimoto K, Kakegawa T, Takahashi H, Tomita Y, Abe M, Yoshimasu Y, Takeuchi H, et al. Usefulness of Modified CEUS LI-RADS for the Diagnosis of Hepatocellular Carcinoma Using Sonazoid. Diagnostics (Basel) 2020;10.
31.
go back to reference Guo HL, Zheng X, Cheng MQ, Zeng D, Huang H, Xie XY, Lu MD, et al. Contrast-Enhanced Ultrasound for Differentiation Between Poorly Differentiated Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Ultrasound Med 2022;41:1213-1225.CrossRefPubMed Guo HL, Zheng X, Cheng MQ, Zeng D, Huang H, Xie XY, Lu MD, et al. Contrast-Enhanced Ultrasound for Differentiation Between Poorly Differentiated Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Ultrasound Med 2022;41:1213-1225.CrossRefPubMed
32.
go back to reference Yuan M, Li R, Zhang Y, Yang L, Zhang X, Tang C, Guo D. Enhancement Patterns of Intrahepatic Cholangiocarcinoma on Contrast-Enhanced Ultrasound: Correlation with Clinicopathologic Findings and Prognosis. Ultrasound Med Biol 2019;45:26-34.CrossRefPubMed Yuan M, Li R, Zhang Y, Yang L, Zhang X, Tang C, Guo D. Enhancement Patterns of Intrahepatic Cholangiocarcinoma on Contrast-Enhanced Ultrasound: Correlation with Clinicopathologic Findings and Prognosis. Ultrasound Med Biol 2019;45:26-34.CrossRefPubMed
33.
go back to reference Zheng W, Li Q, Zou XB, Wang JW, Han F, Li F, Huang LS, et al. Evaluation of Contrast-enhanced US LI-RADS version 2017: Application on 2020 Liver Nodules in Patients with Hepatitis B Infection. Radiology 2020;294:299-307.CrossRefPubMed Zheng W, Li Q, Zou XB, Wang JW, Han F, Li F, Huang LS, et al. Evaluation of Contrast-enhanced US LI-RADS version 2017: Application on 2020 Liver Nodules in Patients with Hepatitis B Infection. Radiology 2020;294:299-307.CrossRefPubMed
Metadata
Title
Nomogram based on Sonazoid contrast-enhanced ultrasound to differentiate intrahepatic cholangiocarcinoma and poorly differentiated hepatocellular carcinoma: a prospective multicenter study
Authors
Shuo Wang
Jundong Yao
Kaiyan Li
Hong Yang
Shichun Lu
Guangzhi He
Wei Wu
Wen Cheng
Tianan Jiang
Hong Ding
Xiang Jing
Yuanyuan Yan
Fangyi Liu
Jie Yu
Zhiyu Han
Zhigang Cheng
Shuilian Tan
Xin Li
Jianping Dou
Yunlin Li
Erpeng Qi
Yiqiong Zhang
Ping Liang
Xiaoling Yu
Publication date
12-07-2023
Publisher
Springer US
Published in
Abdominal Radiology / Issue 10/2023
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-023-03993-z

Other articles of this Issue 10/2023

Abdominal Radiology 10/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.